Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure Journal Article


Authors: Buege, M. J.; Drill, E.; Horwitz, S. M.; LeVoir, A.; Pak, T.; Peterson, T. J.; Dao, P. H.; Matasar, M. J.
Article Title: Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure
Abstract: Objective: To describe the incidence of cardiotoxicity in patients with anthracycline exposure who subsequently receive EPOCH for non-Hodgkin lymphoma (NHL). Methods: We conducted a retrospective cohort study of adults with anthracycline exposure who subsequently received EPOCH for NHL at Memorial Sloan Kettering Cancer Center. The primary outcome was cumulative incidence of arrhythmia, heart failure (HF), left ventricular (LV) dysfunction, or cardiac death. Results: Among 140 patients, most had diffuse large B-cell lymphoma. Inclusive of EPOCH, median cumulative doxorubicin-equivalent dose was 364 mg/m2; exposure was 400 mg/m2 or higher in 41%. With median 36-month follow-up, 23 cardiac events were noted in 20 patients. Cumulative incidence of cardiac events at 60 months was 15% (95% confidence interval [CI]: 9%–21%). When limited to LV dysfunction/HF, cumulative incidence at 60 months was 7% (95% CI: 3%–13%), with most events occurring after the first year. Univariate analysis indicated only history of cardiac disease and dyslipidemia to be associated with cardiotoxicity; no other risk factors, including cumulative anthracycline dose, were identified. Conclusions: In this retrospective cohort, representing the largest experience in this setting with extended follow-up, cumulative incidence of cardiac events was low. Rates of LV dysfunction or HF were particularly low, suggesting infusional administration may mitigate risk despite prior exposure. © 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Keywords: cardiotoxicity; lymphoma; survivorship; non-hodgkin
Journal Title: European Journal of Haematology
Volume: 111
Issue: 1
ISSN: 0902-4441
Publisher: John Wiley & Sons  
Date Published: 2023-07-01
Start Page: 96
End Page: 102
Language: English
DOI: 10.1111/ejh.13971
PUBMED: 36971022
PROVIDER: scopus
PMCID: PMC10634315
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Steven M Horwitz
    645 Horwitz
  2. Matthew J Matasar
    289 Matasar
  3. Esther Naomi Drill
    93 Drill
  4. Terry Kheng Pak
    12 Pak
  5. Michael Buege
    17 Buege
  6. Andrea C. Levoir
    7 Levoir
  7. Phuong Hong Dao
    8 Dao